GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) to include Denmark, Finland, Norway and Sweden. The agreement grants GENESIS Pharma rights to commercialize Alnylam's RNAi therapeutics for cardiomyopathy conditions and rare genetic diseases in these four Nordic markets.

The partnership, originally established in 2019, previously covered 13 Southeast European markets including Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, North Macedonia, Montenegro, Malta, and Kosovo. The expansion brings GENESIS Pharma's total coverage to 17 European markets.

"We are proud of our strong and established partnership with GENESIS Pharma and are delighted to broaden this across the Nordic region," said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam Pharmaceuticals.

Constantinos Evripides, Managing Director of GENESIS Pharma, stated the expansion "marks a significant milestone in our partnership and reflects our ongoing efforts to strengthen our European footprint, building on our three-decade legacy and commitment to biotechnology."

GENESIS Pharma, established in 1997 and based in Athens, Greece, specializes in commercializing biopharmaceutical products for severe and rare diseases across 24 European countries. Alnylam Pharmaceuticals develops RNAi therapeutics, which use RNA interference technology to silence disease-causing genes.

The information was disclosed in a company press release.